Traws Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRAW research report →
About the company
Traws Pharma, Inc. , a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19.
- CEO
- Iain D. Dukes
- IPO
- 2013
- Employees
- 6
- HQ
- Newtown, PA, US
Price Chart
- Market Cap
- $7.02M
- P/E
- -0.88
- P/S
- 0.00
- P/B
- -1.54
- EV/EBITDA
- -0.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 489.90%
- ROIC
- 283.33%
- Revenue
- $2.79M · 1134.51%
- Net Income
- $9.17M · 116.77%
- EPS
- $0.83 · 102.36%
- Op Income
- $-17,875,000
- FCF YoY
- 30.28%
- 52W High
- $3.27
- 52W Low
- $0.64
- 50D MA
- $1.33
- 200D MA
- $1.83
- Beta
- 1.45
- Avg Volume
- 2.36M
Get TickerSpark's AI analysis on TRAW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | ORBIMED ADVISORS LLC | buy | 1,793,187 |
| Apr 16, 26 | ORBIMED ADVISORS LLC | buy | 597,729 |
| Apr 16, 26 | ORBIMED ADVISORS LLC | buy | 597,729 |
| Apr 16, 26 | ORBIMED ADVISORS LLC | buy | 597,729 |
| Mar 8, 26 | Parker Charles Nolan | other | 104,544 |
| Dec 12, 25 | Parker Charles Nolan | other | 61,571 |
| Oct 12, 25 | Parker Charles Nolan | other | 32,406 |
| Dec 12, 25 | Parker Charles Nolan | other | 15,393 |
| Jul 3, 25 | Parker Charles Nolan | other | 0 |
| Mar 8, 26 | Clarke Trafford | other | 33,435 |
Our TRAW coverage
Recent articles, reports, and earnings notes.
No research on TRAW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRAW report →Similar companies
Peers in the same neighborhood.